Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00551135
Registration number
NCT00551135
Ethics application status
Date submitted
26/10/2007
Date registered
30/10/2007
Date last updated
25/01/2021
Titles & IDs
Public title
Surgical Pain After Inguinal Hernia Repair (SPAIHR)
Query!
Scientific title
A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
Query!
Secondary ID [1]
0
0
A0081171
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pain, Postoperative
0
0
Query!
Hernia, Inguinal
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pregabalin
Treatment: Drugs - placebo
Treatment: Drugs - Pregabalin
Treatment: Drugs - Pregabalin
Experimental: 3 -
Placebo Comparator: 4 -
Experimental: 2 -
Experimental: 1 -
Treatment: Drugs: Pregabalin
150 mg BID
Treatment: Drugs: placebo
Placebo
Treatment: Drugs: Pregabalin
75 mg BID
Treatment: Drugs: Pregabalin
25 mg BID
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery
Query!
Assessment method [1]
0
0
m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours: range of 0 (no pain) to 10 (worst imaginable pain).
Query!
Timepoint [1]
0
0
24 hours post surgery
Query!
Secondary outcome [1]
0
0
Numeric Rating Scale (NRS): Current Pain With Movement - Sitting
Query!
Assessment method [1]
0
0
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by sitting (sitting in a standardized fashion after being in a fully supine position); range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [1]
0
0
Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [2]
0
0
Numeric Rating Scale (NRS): Current Pain With Movement - Walking
Query!
Assessment method [2]
0
0
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by walking (rising from sitting position and walking approximately 5 meters or 16 feet at a moderate pace); range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [2]
0
0
Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [3]
0
0
Numeric Rating Scale (NRS): Current Pain With Movement - Coughing
Query!
Assessment method [3]
0
0
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by coughing (coughing two times while sitting); range: 0 (no pain) to 10 (worst pain)
Query!
Timepoint [3]
0
0
Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [4]
0
0
Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing
Query!
Assessment method [4]
0
0
NRS: a self-administered questionnaire to rate pain. AUC from 1 h PS through 48 h PS for ratings of pain caused by movements of sitting, walking, and coughing; Range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [4]
0
0
1 hour through 48 hours post surgery
Query!
Secondary outcome [5]
0
0
Numerical Rating Scale (NRS): Current Pain at Rest
Query!
Assessment method [5]
0
0
NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [5]
0
0
2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 PS
Query!
Secondary outcome [6]
0
0
Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)
Query!
Assessment method [6]
0
0
NRS: a self-administered questionnaire to rate pain. AUC for a single item asking participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [6]
0
0
1 through 48 hours post surgery (PS)
Query!
Secondary outcome [7]
0
0
Numeric Rating Scale (NRS): Average Pain
Query!
Assessment method [7]
0
0
NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate pain on average in the last 24 hours; range: 0 (no pain) to 10 (worst pain).
Query!
Timepoint [7]
0
0
2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 1, 2, 3, 4, 5, 6, and 7 PS
Query!
Secondary outcome [8]
0
0
Time From End of Surgery to First Rescue Medication
Query!
Assessment method [8]
0
0
Rescue medication includes both naproxen and narcotic medication (including tramadol and opioid analgesics). For subjects without use of rescue medication, the time-to-event variable is censored at the Beginning of Taper Visit (Day 7 PS) or at time of withdrawal.
Query!
Timepoint [8]
0
0
Day 1 through Day 7 post surgery
Query!
Secondary outcome [9]
0
0
Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)
Query!
Assessment method [9]
0
0
PADS is a 5-item scale (individual item range: 0-2; higher scores indicating better readiness for hospital discharge). Total score range: 0-10, with 9 or higher indicating eligibility for discharge. End of surgery is time of transfer to post-anesthesia care unit (PACU). Subjects who did not reach a score of 9 on PADS were censored at the date and time of discharge.
Query!
Timepoint [9]
0
0
Day 1
Query!
Secondary outcome [10]
0
0
Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Day 1
Query!
Secondary outcome [11]
0
0
Daily Sleep Interference Rating Scale (DSIRS) Score
Query!
Assessment method [11]
0
0
DSIRS: self-administered 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep [unable to sleep due to pain]) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Performed daily on awakening, prior to taking study medication.
Query!
Timepoint [11]
0
0
Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 post surgery (PS)
Query!
Secondary outcome [12]
0
0
Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery
Query!
Assessment method [12]
0
0
Total cumulative dose of opioids and tramadol administered by any route during surgery and postoperatively. Dose of tramadol calculated as milligrams (mg) of oral morphine equivalent.
Query!
Timepoint [12]
0
0
24, 48, and 72 hours (h) post surgery (PS), and Days 4, 5, 6, and 7 PS
Query!
Secondary outcome [13]
0
0
Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study
Query!
Assessment method [13]
0
0
Total cumulative dose of naproxen calculated in milligrams (mg) from the end of surgery up to and including Day 7 after surgery.
Query!
Timepoint [13]
0
0
End of Surgery through Day 7 post surgery
Query!
Secondary outcome [14]
0
0
Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)
Query!
Assessment method [14]
0
0
OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). The Total Distinct CME score is the sum of CMEs across symptoms (range: 0 [none] to 10 [10 CMEs]); the Cumulative Total Distinct (CT Distinct) CME score is the sum of Total Distinct CME scores at observation and prior observations. The Total CME score is the same as the Total Distinct CME score except that only 1 CME is counted if both nausea and vomiting (or retching) occur (range: 0 [none] to 9 [9 CMEs]).
Query!
Timepoint [14]
0
0
3, 24, and 72 hours (h) Post-Surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [15]
0
0
Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)
Query!
Assessment method [15]
0
0
OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). For individual symptom categories, the number of subjects who experienced at least one CME. Concentrate (concentr).
Query!
Timepoint [15]
0
0
3, 24, and 72 hours (h) post surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [16]
0
0
Subject Global Evaluation of Study Medication (GESM)
Query!
Assessment method [16]
0
0
GESM is a self-administered overall impression (global evaluation) of study medication received for pain; 4 categories: poor, fair, good, and excellent.
Query!
Timepoint [16]
0
0
24 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [17]
0
0
Participants With Wound Healing Complications
Query!
Assessment method [17]
0
0
Investigator-assigned mutually exclusive categories of: 1) no surgical wound complication, 2) superficial incisional surgical site infection, 3) deep incisional surgical site infection, 4) organ or space surgical site infection, or 5) non-infectious wound healing complication.
Query!
Timepoint [17]
0
0
Day 7 post surgery (PS) and up to 30 days PS
Query!
Secondary outcome [18]
0
0
Participants With Physician Contacts Post-discharge
Query!
Assessment method [18]
0
0
Number of participants who answered "yes" to the Post-Surgery Contact question: "From the time you were discharged from the hospital, did you have to contact any type of physician because of pain, difficulty getting up and walking about, or difficulty with passing urine?"
Query!
Timepoint [18]
0
0
24 and 72 hours (h) post surgery (PS)
Query!
Secondary outcome [19]
0
0
Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score
Query!
Assessment method [19]
0
0
Anxiety VAS is a single-item self-administered continuous measure of anxiety using a 100-millimeter (mm) line on which the subject is asked to place a mark indicating the intensity of current anxiety. The score is the distance in mm from the left-most point on the line to the subject's mark; range: 0 (Not at all anxious) at the left-most point to 100 (Extremely anxious) at the right-most point. Performed prior to blood draws.
Query!
Timepoint [19]
0
0
Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h PS; Days 2, 3, 4, 5, 6, 7, 8, and 9 PS
Query!
Secondary outcome [20]
0
0
Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score
Query!
Assessment method [20]
0
0
EQ-5D is a self-administered questionnaire to assess health-related quality of life in 5 domains (mobility, self care, usual activities, pain or discomfort, and anxiety or depression). Scores from the 5 domains are used to calculate a single index value: the Health State Profile Score; range: 0.0 (death) to 1.0 (perfect health), higher scores indicating better health state.
Query!
Timepoint [20]
0
0
Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Query!
Secondary outcome [21]
0
0
Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales
Query!
Assessment method [21]
0
0
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores mean a greater extent of pain catastrophizing.
Query!
Timepoint [21]
0
0
3 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Query!
Secondary outcome [22]
0
0
Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy
Query!
Assessment method [22]
0
0
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all items (range: 0 to 52); higher scores mean a greater extent of pain catastrophizing.
Query!
Timepoint [22]
0
0
Baseline and Days 1 and 7 post surgery (PS)
Query!
Secondary outcome [23]
0
0
Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)
Query!
Assessment method [23]
0
0
PCSS and MCSS are component summary scores from the self-administered SF-12v2 acute health quality of life, norm-based survey. PCSS range: 4.95 to 76.13; MCSS range: -0.79 to 79.69; lowest scores mean very much below and highest scores mean very much above the general population average.
Query!
Timepoint [23]
0
0
Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Query!
Secondary outcome [24]
0
0
Participants With Chronic Postoperative Pain
Query!
Assessment method [24]
0
0
Number of participants who reported surgery-related pain at assessment (by answering 'yes' to a single question: "In the last 24 hours, have you had pain in the area affected by your surgery?")
Query!
Timepoint [24]
0
0
1, 3, and 6 months (mo) post surgery (PS)
Query!
Secondary outcome [25]
0
0
Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
Query!
Assessment method [25]
0
0
m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. Pain interference index score is mean of 7 individual item scores for interference of pain with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life); range: 0 (does not interfere) to 10 (completely interferes with functional activities). Pain severity index score is mean of 4 individual item scores for pain severity (pain right now, and worst, least, and average pain); range: 0 (no pain) to 10 (worst imaginable pain).
Query!
Timepoint [25]
0
0
1, 3, and 6 months (mo) post surgery (PS)
Query!
Secondary outcome [26]
0
0
Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)
Query!
Assessment method [26]
0
0
NPSI: a 12-item self-administered questionnaire to assess the characteristics of neuropathic pain on average in the last 24 hours. 5 subscale scores include: burning spontaneous (spont.) pain, pressing spont. pain, paroxysmal pain, evoked pain, and paresthesia or dysesthesia (paresth/dysesth) (range: 0 [no pain] to 10 [worst pain imaginable]); total score calculated from the 5 pain subscores (range: 0 to 0.5), higher scores meaning worse pain.
Query!
Timepoint [26]
0
0
1, 3, and 6 months (mo) post surgery (PS)
Query!
Eligibility
Key inclusion criteria
- The subject will have elective ( the subject chooses, but does not have to undergo
surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using
mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or
sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local
anesthetic infiltration at the conclusion of surgery. Study surgery should be
anticipated to be in the morning.
- Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as
naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after
surgery.
- The subject will be available for a visit within 72 hours of the day of surgery if not
admitted the night before for baseline assessments before taking any study medication,
and then to receive study medication prior to the day before surgery.
- The subject is expected and agrees to remain at the hospital (or intermediate care
facility) for a minimum of 3 hours following surgery.
Query!
Minimum age
17
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with non elective or emergency surgery (must have the surgery no matter
what), or hernia with incarceration (the trapping of abdominal contents within the
hernia itself).
- Subjects with hernia repair that is not a primary repair. The planned use of nerve
block or spinal/epidural/paravertebral anesthesia or surgery is not planned with
general anesthesia.
- Subjects that are not allowed to receive the anesthesia agents indicated per protocol
and general anesthesia.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
425
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Randwick
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Ontario
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Prince Edward Island
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Quebec
Query!
Country [14]
0
0
India
Query!
State/province [14]
0
0
Gujarat
Query!
Country [15]
0
0
India
Query!
State/province [15]
0
0
Maharashtra
Query!
Country [16]
0
0
India
Query!
State/province [16]
0
0
Tamil Nadu
Query!
Country [17]
0
0
India
Query!
State/province [17]
0
0
Delhi
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Madrid
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Barcelona
Query!
Country [20]
0
0
Sweden
Query!
State/province [20]
0
0
Gavle
Query!
Country [21]
0
0
Sweden
Query!
State/province [21]
0
0
Landskrona
Query!
Country [22]
0
0
Sweden
Query!
State/province [22]
0
0
Mora
Query!
Country [23]
0
0
Sweden
Query!
State/province [23]
0
0
Orebro
Query!
Country [24]
0
0
Sweden
Query!
State/province [24]
0
0
Skelleftea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to test whether pregabalin added to the standard of care with
dosing starting preoperatively and continuing for 1 week post surgery will decrease the
intensity of acute post-operative pain following inguinal hernia repair.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00551135
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00551135
Download to PDF